logo BDSP

Base documentaire

  1. Chemoprevention of gastrointestinal cancer.

    Article - En anglais

    Gastrointestinal cancer remains a significant public health threat in developed countries.

    Even with breath-taking gains in our understanding of the molecular underpinnings of the most common Gl cancers, it is clear that the best hope in the foreseeable future lies in the chemoprevention of recurrent cancer and its associated precursors.

    Colon cancer is an ideal disease for the application of chemopreventive strategies.

    The molecular biology of colon cancer has been well studied and it is an excellent model for the development of chemopreventive interventions.

    This fact allows clinical investigators to utilize what is known about discrete biological phases of colon carcinogenesis to tailor clinical trial protocols that may attenuate a future risk for cancer.

    Among the agents currently in clinical trial testing are anti-oxidants, modulators of metabolism, and anti-proliferatives.

    Current clinical trials have often incorporated the use of biomarkers as intermediate endpoints to assess the efficacy of particular preventives.

    The current status of ongoing colon cancer prevention trials suggests that this disease, in particular, may well be suited to chemopreventive approaches.

    Mots-clés Pascal : Tumeur maligne, Côlon, Rectum, Chimioprophylaxie, Prévention, Vitamine, Antioxydant, Antiinflammatoire non stéroïde, Antagoniste, Prostaglandine, Anticancéreux, Calcium, Oltipraz, Sélénium, Sulfure, Essai clinique, Etats Unis, Amérique du Nord, Amérique, Homme, Appareil digestif pathologie, Intestin pathologie, Côlon pathologie, Rectum pathologie, Arachidonique acide dérivé, Ornithine(2-difluorométhyl)

    Mots-clés Pascal anglais : Malignant tumor, Colon, Rectum, Chemoprophylaxis, Prevention, Vitamin, Antioxidant, Non steroidal antiinflammatory agent, Antagonist, Prostaglandin, Antineoplastic agent, Calcium, Oltipraz, Selenium, Sulfides, Clinical trial, United States, North America, America, Human, Digestive diseases, Intestinal disease, Colonic disease, Rectal disease, Arachidonic acid derivatives

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0067216

    Code Inist : 002B02R02. Création : 14/05/1998.